Time to Prescribe Drugstore Stocks?

With favorable momentum trends and solid industry fundamentals, S&P says shares should continue to perform well

The Standard & Poor's 1500 Drug Retail subindustry index recently saw its relative strength ranking (RSR) rise to three from two, indicating that its trailing 12-month price performance is now in the middle 40% of all 136 subindustry indexes in the S&P 1500 (it had been in the lowest 30%). Year to date through May 31, the S&P Drug Retail Index gained 10.9%, vs. an 8.5% gain for the S&P 1500. In the past 13 weeks, this subindustry index gained 11.9% compared to the market's climb of 8.8%.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.